文献速递病毒性肝炎

接受核苷(酸)类似物治疗的慢性乙型肝炎患者血清乙型肝炎病毒RNA与肝细胞癌风险的关联

Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.
PubMed 文献 · J Infect Dis · 2022-01-01

研究纳入2974例接受核苷(酸)类似物治疗的前瞻性观察性慢性乙型肝炎队列患者,中位随访4.4年,90例发生肝细胞癌。基线可检测HBV RNA者5年肝细胞癌累积发生率4.1% vs 不可检测者1.8%(P=.009),校正风险比(aHR)=2.21(P=.005)。高水平HBV RNA与肝细胞癌风险增加相关,实现HBV RNA不可检测可能有助于改善临床结局,提示其可能是抗HBV治疗的有价值终点。

要点

  • 基线可检测HBV RNA者较不可检测者肝细胞癌风险升高(aHR=2.21,P=.005)。
  • HBV RNA 609-99999和≥100000 copies/mL与肝细胞癌风险递增相关(aHR=2.15和3.05)。
  • 单检测到HBV DNA或RNA、双检测到DNA和RNA者肝细胞癌风险分别较双不可检测者高1.57倍和4.02倍。

核心结论

  • 高水平HBV RNA与接受核苷(酸)类似物治疗患者肝细胞癌风险增加相关。
  • 实现HBV RNA不可检测可能有助于改善临床结局,提示其可能是抗HBV治疗的有价值终点。

研究设计与样本

  • 前瞻性、观察性慢性乙型肝炎队列,纳入2974例接受核苷(酸)类似物治疗的患者。
  • 采用Cox回归分析基线血清HBV RNA对肝细胞癌发生的影响。

主要发现

  • 中位随访4.4年,90例患者发生肝细胞癌。
  • 基线可检测HBV RNA者(n=2072)5年肝细胞癌累积发生率4.1%,不可检测者1.8%(P=.009);aHR=2.21(P=.005)。
  • HBV RNA 609-99999 copies/mL者aHR=2.15,≥100000 copies/mL者aHR=3.05,趋势P=.003(参照不可检测<609 copies/mL)。
  • 单检测到HBV DNA或RNA者aHR=1.57,双检测到DNA和RNA者aHR=4.02,趋势P=.001(参照双不可检测DNA和RNA)。

关键数值与推荐

  • 基线HBV RNA可检测(n=2072)vs 不可检测:5年肝细胞癌累积发生率4.1% vs 1.8%(P=.009)。
  • 基线HBV RNA可检测vs不可检测:aHR=2.21(P=.005)。
  • HBV RNA 609-99999 copies/mL:aHR=2.15;≥100000 copies/mL:aHR=3.05;趋势P=.003。
  • 单检测到HBV DNA或RNA:aHR=1.57;双检测到DNA和RNA:aHR=4.02;趋势P=.001。

临床怎么用

  • 作者认为高水平HBV RNA与接受核苷(酸)类似物治疗患者肝细胞癌风险增加相关。
  • 作者认为实现HBV RNA不可检测可能有助于改善临床结局,提示其可能是抗HBV治疗的有价值终点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether serum hepatitis B virus (HBV) RNA associates with hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients has not been fully elucidated. METHODS: We enrolled 2974 patients receiving nucleos(t)ide analogues (NAs) from a prospective, observational CHB cohort to investigate the effect of serum HBV RNA, measured at study entry (baseline), on HCC development, using Cox regression analyses. RESULTS: During median follow-up of 4.4 years, 90 patients developed HCC. Patients with detectable baseline HBV RNA (n = 2072) exhibited significantly higher HCC risk than those with undetectable level (5-year HCC incidence estimated by Kaplan-Meier method: 4.1% versus 1.8%, P = .009; adjusted hazard ratio [aHR] = 2.21, P = .005). HBV RNA levels of 609-99 999 and ≥100 000 copies/mL were associated with incrementally increasing HCC risk (aHR = 2.15 and 3.05, respectively; P for trend = .003), compared to undetectable level (<609 copies/mL). Moreover, patients with single-detectable either HBV DNA or RNA and double-detectable DNA and RNA had 1.57- and 4.02-fold higher HCC risk, respectively, than those with double-undetectable DNA and RNA (P for trend = .001). CONCLUSIONS: High-level HBV RNA is associated with increased HCC risk in NAs-treated patients. Achieving undetectable HBV RNA may contribute to better clinical outcomes, indicating it could be a valuable endpoint of anti-HBV treatment.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Liu S, Deng R, Zhou B, et al. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy. J Infect Dis. 2022. PMID: 34931674. doi:10.1093/infdis/jiab597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。